吉西他滨联合顺铂治疗Ⅲ、Ⅳ期非小细胞肺癌的临床评价

Clinical observation of stage Ⅲ, Ⅳ NSCLC treated by gemcitabine combined with cisplatin

目的观察吉西他滨（GEM）联合顺铂（DDP）治疗Ⅲ、Ⅳ期非小细胞肺癌（NSCLC）的疗效及毒副反应。方法2000年2月至2005年6月，对79例NSCLC患者采用GP方案化疗，用法：GEM1000mg／m^2第1、8天给药；DDP90mg／m^2分3d，21—28d为1周期，2—3周期评价疗效。结果79例分别完成2—5周期联合化疗，其中完全缓解（CR）0例，部分缓解（PR）为25％（20／79），稳定（SD）为27％（21／79），临床受益反应（CBR）为52％（41／79）。初治的39例中，CBR为56．4％（22／39）；复治40例中，CBR为47．5％（19／40）。毒副反应主要为血液学毒性，以血小板减少或白细胞数降低较为明显。结论GEM联合DDP治疗Ⅲ、Ⅳ期NSCLC，具有良好的疗效及耐受性。

Objective To observe the effects of gemcitabine combined with cisplatin regimen in stage Ⅲ, Ⅳ non-small-cell lung cancer （NSCLC）. Methods From February 2000 to June 2005, 79 patients with advanced NSCLC were treated with GP （GEMZAR 1000 mg/m^2 d1,8; DDP 30 mg/m^2 d1-3）. The course was repeated every 3 weeks for at least 2-3 cycles. Results 2-5 cycles of chemotherapy were performed in all patients, the clinical benefit response （CBR） was 52 %（41/79）, PR was 25 %（20/79）, SD was 27 %（21/79）. The clinical benefit response were 56.4 %（22/39） in the initiate group and 47.5 %（19/40） in the secondary group. Bone marrow suppression was the main toxicities, the major side effects were thrombocytopenia and leukopenia. Conclusion The combination of gemcitabine and cisplatin is an effective and tolerable chemotherapy regimen for patients with advanced NSCLC.